Pharmaceutical Industry in
Baar
65 companies in Pharmaceutical Industry based in Baar — name and year of registration from the commercial register.
50 of 65 companies
Biogen Management Services GmbH
Since 2008 · 1–10 empl.4.5(12)
Biogen Management Services GmbH is a biotechnology company that develops and markets medicines for difficult-to-treat diseases. Its focus includes therapeutic areas such as neurology, immunology and rare diseases, including multiple sclerosis, spinal muscular atrophy and Friedreich’s ataxia.
Biogen International GmbH
Since 2007 · 21–50 empl.4.5(12)
Biogen International GmbH is identified on the company's website as Biogen's international headquarters for Europe and Canada. The organisation researches, develops and markets biopharmaceutical medicines, focusing on neurology, neuropsychiatry, immunology and rare diseases, with products and pipeline items covering areas such as Friedreich's ataxia, multiple sclerosis and spinal muscular atrophy.
axapharm ag
Since 2016 · 51–100 empl.5.0(3)
axapharm ag supplies generics, prescription and over-the-counter medicines as well as non-prescription products, and provides services to pharmacies, drugstores and hospitals.
GlaxoSmithKline AG
Since 1952 · 101–500 empl.4.0(4)
GlaxoSmithKline AG develops and markets specialty and general medicines as well as vaccines to prevent and treat disease. The company’s therapeutic focus areas include respiratory conditions, immunology and inflammation, oncology, HIV and infectious diseases.
Pharmact Holding AG
Since 1988 · 1–10 empl.
The core activity of Pharmact AG is the development and application of innovative medical solutions, particularly in the areas of atherosclerosis, diabetes mellitus, and severe liver diseases. The company develops genetically optimized enzymes and point-of-care tests (POCT) for the diagnosis and treatment of diseases, such as familial hypercholesterolemia. The core activity also includes research and development of new therapies and prevention products, as well as the commercial marketing of these products.
Biogen Switzerland AG
Since 1996 · 51–100 empl.
The core activity of Biogen is the research, development and production of medicines, in particular large and small molecular therapeutics, as well as biosimilars, with a focus on the treatment of severe diseases such as neurology, neuropsychiatry, immunology and rare diseases.
PHT Pharmaceutical AG
Since 2003 · 1–10 empl.
PHT Pharmaceutical AG is a contract research, development and manufacturing organization (CRDMO) and chemical supplier offering CRO and CDMO services, process development and cGMP manufacturing, strategic sourcing, logistics, and quality/regulatory support for pharmaceutical, agrochemical and specialty chemical customers.
Alexion Pharma GmbH
Since 2007 · 21–50 empl.
The core activity of Alexion is the development and provision of life-changing therapies for people with rare diseases. The company focuses on researching, developing and delivering medicines tailored to the needs of patients with rare diseases, and strives to improve the quality of life of these individuals.
Ferring AG
Since 2007 · 21–50 empl.
Ferring AG is a biopharmaceutical company that develops medicines and therapies for gastroenterology, urology and reproductive medicine.
Clinuvel AG
Since 2008 · 21–50 empl.
The core activity of CLINUVEL is the development, manufacture and marketing of pharmaceutical products, in particular the product SCENESSE, as well as the expansion of the business into the cosmetics sector and other services within an integrated business model.
ViiV Healthcare GmbH
Since 2009 · 11–20 empl.
The core activity of ViiV Healthcare is the development, manufacture and marketing of medicines for the treatment of HIV and AIDS. The company is exclusively focused on combating HIV and AIDS and strives to leave no person living with HIV behind.
Stallergenes Greer International AG
Since 2013 · 11–20 empl.
The core activity of Stallergenes Greer is the development, manufacture and marketing of products for allergology and specifically for allergen immunotherapy (AIT). The company is a world leader in allergen and AIT products and has a significant global presence.
Bluestone Pharma GmbH
Since 2013 · 11–20 empl.
The core activity of Bluestone Pharma is the development, manufacture and marketing of medical probiotics, in particular oral probiotics, used to treat and prevent various health conditions. The company offers turnkey solutions and private label options to customers and focuses on delivering scientifically proven health benefits through unique probiotic strains in areas with unmet needs.
Plasmaconcept GmbH
Since 2015 · 11–20 empl.
Plasmaconcept is a medical technology company specializing in the development and marketing of products for orthopedics and sports medicine. The company's core activity includes the manufacture and distribution of medical products such as viscosupplements, cell therapies, cryotherapy products, and surgical solutions for the treatment of joint and bone disorders.
Indivior Schweiz AG
Since 2015 · 1–10 empl.
Indivior Schweiz AG is a specialty pharmaceutical company focused on evidence-based treatment and advancing understanding of opioid use disorder (OUD). It develops and provides therapies, including buprenorphine-based treatments, and conducts research to support long-term recovery.
Extrovis AG
Since 2016 · 101–500 empl.
Extrovis AG is a global Contract Research, Development & Manufacturing Organization (CRDMO) that develops and manufactures complex specialty therapeutics, including sterile antibiotics, oncology and cytotoxic formulations, and female hormone products. The company provides R&D, regulated-market manufacturing (USFDA, EU‑GMP) and supply‑chain and regulatory support across drug substances and finished dosage forms.
Cancer Research and Biotechnology AG
Since 2017 · 11–20 empl.
The core activity of Cancer Research and Biotechnology AG is the development of oncological drugs to combat aggressive types of cancer with high unmet medical needs. The company aims to improve the patient journey through an accelerated clinical regulatory pathway and reduce the burden of conventional treatments.
TAP Pharmaceuticals AG
Since 2017 · 21–50 empl.
The core activity of Axarlabs/TaP Pharmaceuticals AG is the end-to-end development of pharmaceutical products, from formulation and process development to marketing. This also includes services such as clinical trials, regulatory strategies, analytics, intellectual property rights and quality management. The company also offers customized project management support and portfolio selection as well as commercial evaluation.
Centenara Labs AG
Since 2019 · 11–20 empl.
The core activity of Centenara Labs AG is the development and investment in therapies that combat age-related diseases such as cancer, muscle weakness, vision loss, and cognitive impairments. The company focuses on researching and developing medications that address the so-called "Hallmarks of Aging" to improve the health and well-being of older people and extend their lifespan.
OrchestratePharma GmbH
Since 2020 · 1–10 empl.
OrchestratePharma GmbH is a drug development company focused on drug repurposing (DRPx) of known molecular entities, notably fexofenadine. It is developing a topical product, FexoTopic (OP2101), for treatment of mild to moderate atopic dermatitis and pursues strategic partnerships with CROs, data-science and DRPx collaborators to accelerate development.
Taiho Oncology Europe GmbH
Since 2021 · 11–20 empl.
The core activity of Taiho Oncology Europe GmbH is the development, manufacture and marketing of cancer medications and other pharmaceuticals, particularly in the fields of oncology, allergology and urology. The company focuses on researching and developing innovative cancer treatments and also offers consumer products for healthcare.
"Lysoform" Schweizerische Gesellschaft für Antisepsie AG
Since 2021 · 11–20 empl.
The core activity of Lysoform is the development, manufacture and distribution of disinfectants and hygiene products for the medical sector, particularly for the disinfection of hands, skin, surfaces, instruments and equipment.
Micreos Pharmaceuticals AG
Since 2021 · 1–10 empl.
Micreos Pharmaceuticals AG develops engineered endolysins and recombinant protein therapeutics for dermatological conditions. The company’s lead candidate, MEndoB, targets Staphylococcus aureus in atopic dermatitis and preclinical data indicate safety, target specificity, efficacy including activity against biofilms, and a low propensity for resistance.
GlaxoSmithKline AG Zweigniederlassung Baar/Zug
Since 2019 · 51–100 empl.4.5(2)
GlaxoSmithKline AG Zweigniederlassung Baar/Zug is a branch of the biopharmaceutical company GSK, engaged in research, development and commercialization of medicines, vaccines and healthcare products, with R&D focused on respiratory, immunology and inflammation, oncology, HIV and infectious diseases.
Vesifact AG
Since 1994 · 11–20 empl.5.0(2)
The core activity of Vesifact AG is the development and application of technologies to improve the bioavailability of poorly absorbed active ingredients in the areas of dietary supplements, pharmaceuticals, cosmetics and medical devices. In particular, the company focuses on the development of solutions to optimize the bioavailability of cannabinoids and other active ingredients through the application of its patented VESIsorb technology.
Vaxcyte Switzerland GmbH
Since 2023 · 1–10 empl.
Vaxcyte Switzerland GmbH is a vaccine development company focused on preventing bacterial infections such as pneumococcal disease, Group A Strep and Shigella. The company develops vaccine candidates and uses a cell-free protein synthesis platform to support the design and manufacture of complex vaccines.
Recipharm Group AG
Since 2025 · 1–10 empl.
Recipharm Group AG is a CDMO company focused on pharmaceutical development and manufacturing. The company provides development and production services for solids, semi-solids and liquids, as well as sterile fill-finish solutions, specialised products and additional supporting services.
AstraZeneca AG
Since 1999 · 101–500 empl.2.3(21)
AstraZeneca AG is the affiliate of AstraZeneca PLC; its core business is the development and marketing of medicines across oncology, cardiovascular, renal and metabolic diseases, respiratory and immunology, vaccines and immunotherapies, and rare diseases.
EQX Healthcare AG
Since 2024 · 1–10 empl.
EQX Healthcare AG produces and sells natural dietary supplements for horses, developing formulations with veterinarians to support digestive health, metabolism, respiratory function and the musculoskeletal system.
Therakles Pharmaceuticals AG
Since 2024 · 1–10 empl.
Therakles Pharmaceuticals AG develops radiopharmaceutical therapies for cancer treatment and combines approaches from nuclear medicine and drug discovery. The company focuses on targeted radiopharmaceutical applications.
Recipharm Holding GmbH
Since 2026 · 1–10 empl.
Recipharm Holding GmbH is a pharmaceutical contract development and manufacturing organization (CDMO). The company provides development, manufacturing and specialised services for solid, sterile and advanced biologic dosage forms, together with analytical, technology transfer and regulatory support.
AstraZeneca Ireland Limited, Dublin, Zweigniederlassung Baar
Since 2024 · 11–20 empl.2.3(21)
AstraZeneca Ireland Limited, Dublin, Zweigniederlassung Baar is AstraZeneca’s Swiss branch that provides medicines to patients in Switzerland and collaborates with research partners and healthcare stakeholders to support patient care, early disease detection (particularly cancer) and sustainability initiatives.
HealthWatch Swiss AG
Since 2007 · 11–20 empl.
The core activity of HealthWatch Swiss is the development, licensing and marketing of pharmaceuticals, particularly through strategic partnerships and licenses, to provide patients with access to high-quality medications while simultaneously opening up new business areas to ensure sustainable growth.
Scalepharm AG
Since 2019 · 11–20 empl.
The core activity of Scalepharm is the development, registration, manufacture and marketing of generic finished medicinal products, in particular prescription-only medicines, which are distributed through retail pharmacies and hospitals.
Aalto Pharma AG
Since 2022 · 1–10 empl.
Aalto Pharma AG is a Swiss pharmaceutical company focused on supramolecular API delivery for treating topical infections in humans and animals. The company develops and manufactures supramolecular molecules and a patented delivery platform, which the website describes as non-toxic, non-comedogenic and non-cauterising, and reports bactericidal activity against antibiotic-resistant bacteria such as E. coli, A. baumannii and P. aeruginosa.
Farmak Group AG
11–20 empl.
Farmak Group AG develops and manufactures pharmaceutical products across a wide range of therapeutic areas, including prescription medicines, over-the-counter products and medical devices. Its portfolio includes tablets, injection and infusion solutions, nasal and eye drops, sprays and other dosage forms.
Scintec Diagnostics GmbH
Since 1997 · 1–10 empl.
Scintec Diagnostics GmbH is a company whose website only publishes a notice about a transaction with Telix Pharmaceuticals Limited. No further details about products, services, or its core business are provided on the site.
Agios International GmbH
Since 2015 · 1–10 empl.
Suxea GmbH
Since 1997 · 1–10 empl.
Movi Health GmbH
Since 2009 · 1–10 empl.
CRO Management AG
Since 2009 · 1–10 empl.
Vet Medic Animal Health AG
Since 2011 · 1–10 empl.
Phoenixus AG
Since 2014 · 1–10 empl.
Medex Pharma AG
Since 2014 · 1–10 empl.
Kaybiotix GmbH
Since 2017 · 1–10 empl.
Kaper Pharma AG
Since 2018 · 1–10 empl.
Valves Engineering GmbH
Since 2019 · 1–10 empl.
Everest Medical Innovation GmbH
Since 2021 · 1–10 empl.
Refinety Pharma GmbH
Since 2021 · 1–10 empl.
Optifye Therapeutics AG
Since 2021 · 1–10 empl.
Pharmaceutical Industry in Baar
Pharmaceutical Industry in the region
Point size by number of companies per place.
Source: commercial register (Zefix) · as of October 10, 2026
Pharmaceutical Industry in other places
By canton